# PBD Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pbd-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Suffolk, UK
- Website: www.pbdbio.com
- Total disclosed funding: $0.5M
- Latest round: Seed (Jun 27, 2018)
- Investors on record: 2

## About

Based in the UK, PBD Biotech Ltd specializes in innovative bacteriophage-based diagnostics, focusing on tuberculosis detection through its flagship product, Actiphage, which aids healthcare professionals in effective disease management.Founded in 2014 and headquartered in Suffolk, UK, PBD Biotech Ltd develops advanced diagnostic solutions targeting mycobacteria. The company has engaged in 4 deals, with its most recent funding round on March 26, 2021, where it raised GBP 2.3 million from investors including the British Business Bank and Foresight Group Holdings. Jane Theaker leads the firm as CEO.PBD Biotech specializes in the development of bacteriophage-based diagnostics, with its flagship product, Actiphage. This proprietary technology is designed to detect mycobacteria, the pathogen responsible for tuberculosis, in blood samples, serving critical end-use cases in both human and veterinary medical sectors. The innovative approach, leveraging novel bacteriophage technology, provides rapid and reliable diagnostic results, aiding healthcare professionals in decision-making. PBD Biotech targets various geographical markets, including the United Kingdom, Europe, and regions with a significant tuberculosis burden.Details regarding the revenue structure of PBD Biotech are not publicly disclosed. The company primarily engages in transactions with healthcare providers, diagnostic laboratories, and governmental health agencies. Its Actiphage product is expected to play a significant role in partnerships with hospitals and clinics, facilitating essential diagnostic testing in tuberculosis management and treatment strategies. Specific pricing and transaction details of their flagship product have not been publicly specified.Following its GBP 2.3 million funding round on March 26, 2021, PBD Biotech Ltd plans to further develop the Actiphage test for tuberculosis towards validation by the World Organisation for Animal Health. This funding will support upcoming initiatives, including potential market expansion and enhancing the product pipeline to meet the needs of healthcare sectors in new geographical regions.

## Funding rounds

- Seed, Jun 27, 2018, $0.2M — Anglia Capital Group
- Seed, Aug 1, 2017, $0.3M — Anglia Capital Group, Cambridge Agritech Ltd

## Investors

- Anglia Capital Group (https://capitalatlas.ai/funds/anglia-capital-group) — Seed
- Cambridge Agritech Ltd — Seed